ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to this new study presented at ACC 2021 simultaneously published in the Lancet.

Renal denervation reduces ambulatory daily systolic blood pressure by 8 mmHg vs 3 mmHg in the sham procedure branch.  This translates into a mean 4.5 mmHg reduction, which results significative (p=0.02).

In addition, there was significant reduction to 24 ambulatory systolic blood pressure, as well as office blood pressure. 

Even though all patients included in the study had been treated with a combination of at least 3 drugs (one of them a diuretic) their blood pressure readings still remained over 150 mmHg.

After the disappointing outcomes of SYMPLCITY HTN-3, the technique was considerably improved and there are now studies with positive results. The device used in RADIANCE-HTN TRIO is assisted by ultrasound to apply 2 or 3 7-second circumferential applications to the renal artery. 

All eligible patients for this study were changed to a fix drug scheme including a calcium beta blocker, an angiotensin inhibitor, and a thiazide diuretic. If after 4 weeks patients continued to present daily hypertension readings over 135/85 mmHg, they were randomized to ultrasound renal denervation vs. the sham procedure. 


Read also: ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI.


989 patients were enrolled, and 69 were finally randomized to denervation and 67 to the sham procedure. This was basically because after 4 weeks researchers were able to reach blood pressure targets.

At 2 months, the active Branch saw a significant reduction of all hypertension variables, including the primary end point of ambulatory daytime blood pressure. 

The only adverse event was a femoral access site pseudoaneurysm in the denervation Branch. 

RADIANCE-HTN-TRIO

Original Title: Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomized, multicenter, single-blind, sham-controlled trial.

Reference: Azizi M et al. Presentado en el congreso de la ACC 2021 y publicado simultáneamente en Lancet 2021; Epub ahead of print. DOI:https://doi.org/10.1016/S0140-6736(21)00788-1.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...